EICHORCondition: Adult Refractory Secondary Hemophagocytic Lymphohistiocytosis · Secondary Hemophagocytic Lymphohistiocytosis · HLH · Sponsor: Fudan University
The goal of this observational study is to learn if interferon-gamma monoclonal antibody combined with dexamethasone works to treat adults with refractory secondary hemophagocytic lymphohistiocytosis (HLH). The main questions it aims to answer are: How well does this treatment help patients recover from refractory secondary HLH? How safe is this treatment for these patients? Participants will receive interferon-gamma monoclonal antibody and dexamethasone as part of their clinical care. Researchers will monitor participants with regular blood tests, physical exams, and safety checks for up to 8 weeks of treatment. They will collect information about how participants respond to treatment and any side effects that occur. This study will include about 22 adult participants at Huadong Hospital Affiliated to Fudan University.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Age ≥ 18 years * Confirmed diagnosis of secondary hemophagocytic lymphohistiocytosis (HLH) according to HLH-2004 criteria * Refractory HLH defined as inadequate response or progression after at least 2 weeks of standard first-line or second-line therapy * Able to provide written informed consent Exclusion Criteria: * Active infection with mycobacteria, histoplasma, CMV, herpes zoster, or HIV * Left ventricular ejection fraction \< 50% * Concurrent use of other anti-neoplastic or investigational agents * Other uncontrolled infections judged by the investigator * Psychiatric disorders or poor protocol compliance
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Huadong Hospital, Fudan University | Shanghai, Shanghai Municipality, China | — |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07531069